Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007091 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
A Phase 1 study of Healthy Volunteers, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
- 4
- Study locations
NCT07007091 is a Phase 1 study of Healthy Volunteers that has completed, run by AbbVie. The registered enrollment target is 260 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (46% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT07007091, a Phase 1 study of Healthy Volunteers, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
Conditions Studied
Interventions
- DRUG Risankizumab
Study Locations (4)
Florida
- Cpmi /Id# 276490 - Miami
Illinois
- Acpru /Id# 276043 - Grayslake
Nevada
- Ppd - Las Vegas Research Unit /ID# 276565 - Las Vegas
Texas
- PPD Phase I Clinic /ID# 276525 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2026-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007091
The ClinicalTrials.gov registry entry for NCT07007091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (46% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which Risankizumab is the first listed.
NCT07007091 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Illinois, Nevada.
Frequently Asked Questions
What is clinical trial NCT07007091 about?
NCT07007091 is a clinical study titled "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants". This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
What is the current status of trial NCT07007091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2025-06-12. Estimated completion is 2026-01-15.
What conditions does trial NCT07007091 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT07007091?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT07007091?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007091 being conducted?
This trial has 4 study locations across Florida, Illinois, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.